-20%
Description
GIP/GLP-1 receptor agonist (dual incretin). Half-life approximately 5 days, subcutaneous injection typically once weekly.
Effect:
- Severe appetite suppression and weight loss
- Improved insulin sensitivity and blood sugar control
- Slowed gastric emptying
- Potential cardiovascular benefits
Dosage:
- Starting dose: 2.5mg/week (titration over 4 weeks)
- Maintenance: 5-10mg/week
- Maximum: up to 15mg/week
Additional information
| Active Ingredient | Tirzepatide |
|---|---|
| Package size | 10IU |
Related products
-34%
-18%
-33%